Journal article
Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia
JB Lew, DJB St. John, FA Macrae, JD Emery, HC Ee, MA Jenkins, E He, P Grogan, M Caruana, D Sarfati, MJE Greuter, VMH Coupé, K Canfell
International Journal of Cancer | WILEY | Published : 2018
DOI: 10.1002/ijc.31314
Abstract
The Australian National Bowel Cancer Screening Program (NBCSP) will fully roll-out 2-yearly screening using the immunochemical Faecal Occult Blood Testing (iFOBT) in people aged 50 to 74 years by 2020. In this study, we aimed to estimate the comparative health benefits, harms, and cost-effectiveness of screening with iFOBT, versus other potential alternative or adjunctive technologies. A comprehensive validated microsimulation model, Policy1-Bowel, was used to simulate a total of 13 screening approaches involving use of iFOBT, colonoscopy, sigmoidoscopy, computed tomographic colonography (CTC), faecal DNA (fDNA) and plasma DNA (pDNA), in people aged 50 to 74 years. All strategies were evalua..
View full abstractGrants
Awarded by Australian Government
Funding Acknowledgements
Grant sponsor: Australian Government Research Training Program Scholarship (formally known as Australian Postgraduate Awards) (to J.B.L.), Translational Cancer Research Network (TCRN) Top-up scholarship, supported by Cancer Institute NSW (to J.B.L.), National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (to E.H.), NHMRC Career Development Fellowships (CDFs) (to K.C.), Cancer Council NSW, Department of Health, Australian Government; Grant numbers: APP1007994 and APP1082989